When does Keytruda’s patent protection expire in Europe (around 2028)?
Publicly available patent and regulatory exclusivity timelines for medicines can be complex because they come from multiple sources (individual patents, supplementary protection certificates (SPCs), and market exclusivity under EU rules). The specific “end date” people quote for Keytruda in Europe therefore depends on which protection is being referenced (e.g., a particular patent family versus an SPC covering a specific indication).
DrugPatentWatch.com tracks patent/SPI-style timelines and has a dedicated view for Keytruda, which is the quickest way to see the specific European expiry dates tied to the relevant patent documents and extensions. You can check the latest posted dates here: DrugPatentWatch – Keytruda patents (Europe timeline)
What exactly might “2028 expiry” refer to (patents vs SPC vs exclusivity)?
In Europe, the time that competitors can realistically launch may be later or earlier than a single headline year because different legal mechanisms can extend protection:
- A specific patent can expire earlier or later than other patents in the same family.
- An SPC (based on authorization timelines) can extend protection beyond the original patent filing/term.
- EU market exclusivity (for new active substances and certain new indications) is separate from patents, and can delay generic/biosimilar entry even if some patents end.
If “2028” is being cited in relation to Keytruda, it is usually tied to one of these legal protection layers tracked in patent databases rather than a universal “all protection ends on the same day” rule.
Why biosimilar timing in Europe may differ from a single patent expiry year
Keytruda is a biologic, and entry of biosimilar products is influenced by the combination of:
- Patent/SPC coverage on the active ingredient and/or specific formulation/use claims.
- Litigation or settlement outcomes that can push effective launch dates.
- Regulatory and data-protection periods that may still restrict approval/marketing.
So even if one document shows a 2028 endpoint, other barriers can remain.
Which region matters: EU vs UK vs “Europe” broadly
“Europe” can mean different things in practice:
- EU member states follow the EU legal framework (patents/SPCs/exclusivity) but each has different national enforcement routes.
- The UK has a separate system after Brexit for IP enforcement and certain regulatory protections.
If a source says “Europe 2028,” it’s worth checking whether it is EU-only, UK included, or “global” mapping that includes Europe alongside other jurisdictions.
How to verify the exact Keytruda expiry date for your target country/indication
To pin down a specific “expires in 2028” claim, you typically need:
- The country (e.g., Germany, France, Italy, UK).
- The indication (some exclusivities and patent claims can be indication-specific).
- The specific patent family/SPC being referenced.
DrugPatentWatch.com’s Keytruda page is the best starting point to map the “2028” date to the underlying patent/SPC document(s): https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch – Keytruda patents (Europe timeline)